| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085377303 |
| P356 | DOI | 10.1007/S11926-017-0664-6 |
| P698 | PubMed publication ID | 28488228 |
| P2093 | author name string | James E Peacock | |
| Rachel M Wolfe | |||
| P2860 | cites work | Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients | Q24193204 |
| Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention | Q24791788 | ||
| Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis | Q33578596 | ||
| Trimethoprim-sulfamethoxazole | Q33686990 | ||
| Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy | Q34004622 | ||
| Efficacy of remission-induction regimens for ANCA-associated vasculitis | Q34037683 | ||
| Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group | Q34062588 | ||
| Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis | Q34320322 | ||
| Cyclophosphamide versus placebo in scleroderma lung disease. | Q34540647 | ||
| Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome | Q34577534 | ||
| Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study | Q34756501 | ||
| Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series | Q34970288 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
| Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death | Q35793693 | ||
| Colonization by Pneumocystis jirovecii and its role in disease | Q35940586 | ||
| Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement | Q36464204 | ||
| Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review | Q36691113 | ||
| Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period | Q36828260 | ||
| Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials | Q36931056 | ||
| Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature | Q37234955 | ||
| Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review | Q37740822 | ||
| Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis | Q37768109 | ||
| Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis | Q38197448 | ||
| Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases | Q38221817 | ||
| Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis | Q38245616 | ||
| Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis | Q38334787 | ||
| Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid | Q38364778 | ||
| Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population | Q38848880 | ||
| Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. | Q38992555 | ||
| Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study | Q39214252 | ||
| Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality | Q39499935 | ||
| Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection | Q39547138 | ||
| Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases | Q40291551 | ||
| Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection | Q40294167 | ||
| Pneumocystis carinii pneumonia in patients with connective tissue disease. | Q40477596 | ||
| EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. | Q40684657 | ||
| Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. | Q40705059 | ||
| Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients | Q41362507 | ||
| Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis | Q41676109 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis | Q44063076 | ||
| Frequency of adverse drug reactions in patients with systemic lupus erythematosus. | Q44334699 | ||
| Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia | Q44463272 | ||
| Wegener's granulomatosis: experience from a Brazilian tertiary center | Q45099806 | ||
| Antibiotic allergy in systemic lupus erythematosus: a case-control study | Q45260710 | ||
| A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis | Q46556046 | ||
| Incidence rate and causes of infection in Thai systemic sclerosis patients. | Q51331191 | ||
| Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients | Q57612951 | ||
| Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy | Q70828301 | ||
| Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus | Q71572888 | ||
| Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease | Q73330919 | ||
| A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis | Q73994647 | ||
| Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy | Q79211608 | ||
| Opportunistic infections in polymyositis and dermatomyositis | Q81629256 | ||
| Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? | Q83975551 | ||
| Recent-onset systemic lupus erythematosus complicated by acute respiratory failure | Q84966540 | ||
| Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases | Q85016620 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 35 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? | |
| P478 | volume | 19 |
| Q64112467 | Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections |
| Q92464818 | Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation |
| Q91977839 | Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras |
| Q88887041 | Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis |
| Q64056635 | Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases |
| Q93374087 | Therapy and Management of Pneumocystis jirovecii Infection |
Search more.